Single center, single arm pilot trial to test the feasibility, safety and efficacy of
NeoTIL-ACT combined with low-dose irradiation (LDI) in patients with advanced, recurrent or
metastatic solid tumors.
The trial is based on lymphodepleting chemotherapy followed by LDI, and then ACT utilizing ex
vivo expanded TIL, enriched for tumor antigen specificity (NeoTIL), in combination with high
dose Interleukin-2 (IL-2) (optional, depending on patient's tolerance).
LDI will be administered once to metastatic lesions using tomotherapy.